Atopic dermatitis is a common skin disease that significantly affects quality of life. For many years, atopic dermatitis treatment in China included only conventional topical/systemic agents and no targeted therapies were available. However, the disease market is poised to see significant growth over the 2019-2029 forecast period, fueled by the uptake of recently launched as well as several upcoming targeted therapies in China. Dupilumab, an IL-4/13 inhibitor recently approved by the NMPA for moderate to severe atopic dermatitis, is the most notable of these agents. Nonetheless, despite this growth, a high unmet need for targeted agents will remain in the market. In addition, with the ongoing reforms in the regulatory and access and reimbursement landscape of China, multinational companies are likely to be increasingly incentivized to enter the Chinese atopic dermatitis market.
Primary research: Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with dermatologists and pediatricians.
Epidemiology: Diagnosed prevalence of atopic dermatitis in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
Forecast: Ten-year, annualized, drug-level sales and patient shares of key atopic dermatitis therapies through 2029, based on primary and secondary market research to formulate bottom-up assumptions.
Emerging therapies: Phase III/PR: 3 agents; Phase II: 3 agents; coverage of selectearly-phase products.
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.